Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 110, 104268
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (GM073646)
This publication has 36 references indexed in Scilit:
- Phosphorylation-Mediated Regulation of Alternative Splicing in CancerInternational Journal of Cell Biology, 2013
- Global analysis of genome, transcriptome and proteome reveals the response to aneuploidy in human cellsMolecular Systems Biology, 2012
- Molecular genetic analysis of Down syndromeHuman Genetics, 2009
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR ExperimentsClinical Chemistry, 2009
- Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down SyndromeJournal of Biological Chemistry, 2008
- Classification of Human Chromosome 21 Gene-Expression Variations in Down Syndrome: Impact on Disease PhenotypesThe American Journal of Human Genetics, 2007
- Understanding the Basis for Down Syndrome PhenotypesPLOS Genetics, 2006
- NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21Nature, 2006
- Cardiac Troponin T Isoforms Affect the Ca2+ Sensitivity of Force Development in the Presence of Slow Skeletal Troponin IJournal of Biological Chemistry, 2004
- Cardiac Troponin T Isoforms Affect the Ca2+Sensitivity and Inhibition of Force DevelopmentJournal of Biological Chemistry, 2002